Skip to Main Content

Last September, Aegerion Pharmaceuticals (AEGR) agreed to pay $40 million to settle civil and criminal charges of illegally marketing a pricey cholesterol medicine, failing to adhere to a regulatory safety program, and misleading investors.

The settlement stemmed from a whistleblower lawsuit filed by three former employees, including Tricia Mullins, who last June had already taken a position with Horizon Pharma (HZNP). But a few weeks after the Aegerion deal was announced, Mullins lost her new job.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED